Welcome to our clinical trial platform informing about our research of tepotinib. Here, you will find information about tepotinib, an oral drug that blocks the activity of the MET protein in cells, which is currently being studied in clinical trials of cancer that has changes to the MET gene.
Tepotinib is under clinical investigation in various countries. The safety and efficacy of tepotinib must be investigated following the respective national regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the health authority in your country.
A phase 2 clinical study of tepotinib combined with osimertinib in patients with advanced or metastatic MET-amplified non-small cell lung cancer (NSCLC) with activating changes in the EGFR gene and resistance to prior osimertinib therapy
ClinicalTrials.gov: NCT03940703
Location: Asia, Europe, North America
Status:
ACTIVE, NOT RECRUITING
US Medical Information: 888-275-7376 - eMediUSA@emdserono.com
Global Communication Center: +49 6151 72 5200 - service@emdgroup.com
Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com
A phase 2 clinical study of tepotinib in patients with advanced (locally advanced or metastatic) non-small cell lung cancer (NSCLC) with changes in the MET gene.
ClinicalTrials.gov: NCT02864992
Location: Asia, Europe, North America
Status:
ACTIVE, NOT RECRUITING
US Medical Information: 888-275-7376 - eMediUSA@emdserono.com
Global Communication Center: +49 6151 72 5200 - service@emdgroup.com
Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com